Genmab CEO about wonder drug: ”It’s incredible”
Genmab has raised its guidance for the third time this year and it could be hiked once more before the close of 2016. The biotech’s CEO says sales of its oncology product Darzalex are “earth shattering” and already looks forward to presenting an heir to the budding blockbuster.
BY LOUISE WENDT JENSEN
Jan van de Winkel, CEO of Danish biotech company Genmab, rates the quarterly report the company delivered last week as a nine out of 10.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
